1. Home
  2. ZBAI vs BCTX Comparison

ZBAI vs BCTX Comparison

Compare ZBAI & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZBAI
  • BCTX
  • Stock Information
  • Founded
  • ZBAI 2015
  • BCTX 2014
  • Country
  • ZBAI United States
  • BCTX Canada
  • Employees
  • ZBAI N/A
  • BCTX N/A
  • Industry
  • ZBAI Professional Services
  • BCTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZBAI Consumer Discretionary
  • BCTX Health Care
  • Exchange
  • ZBAI Nasdaq
  • BCTX Nasdaq
  • Market Cap
  • ZBAI 17.3M
  • BCTX 16.1M
  • IPO Year
  • ZBAI N/A
  • BCTX N/A
  • Fundamental
  • Price
  • ZBAI $0.49
  • BCTX $3.44
  • Analyst Decision
  • ZBAI
  • BCTX Strong Buy
  • Analyst Count
  • ZBAI 0
  • BCTX 1
  • Target Price
  • ZBAI N/A
  • BCTX $32.00
  • AVG Volume (30 Days)
  • ZBAI 962.4K
  • BCTX 759.0K
  • Earning Date
  • ZBAI 03-13-2025
  • BCTX 06-17-2025
  • Dividend Yield
  • ZBAI N/A
  • BCTX N/A
  • EPS Growth
  • ZBAI N/A
  • BCTX N/A
  • EPS
  • ZBAI N/A
  • BCTX N/A
  • Revenue
  • ZBAI $670,000.00
  • BCTX N/A
  • Revenue This Year
  • ZBAI N/A
  • BCTX N/A
  • Revenue Next Year
  • ZBAI N/A
  • BCTX N/A
  • P/E Ratio
  • ZBAI N/A
  • BCTX N/A
  • Revenue Growth
  • ZBAI 67.50
  • BCTX N/A
  • 52 Week Low
  • ZBAI $0.47
  • BCTX $2.81
  • 52 Week High
  • ZBAI $2.50
  • BCTX $29.40
  • Technical
  • Relative Strength Index (RSI)
  • ZBAI N/A
  • BCTX 48.89
  • Support Level
  • ZBAI N/A
  • BCTX $3.23
  • Resistance Level
  • ZBAI N/A
  • BCTX $3.69
  • Average True Range (ATR)
  • ZBAI 0.00
  • BCTX 0.27
  • MACD
  • ZBAI 0.00
  • BCTX 0.05
  • Stochastic Oscillator
  • ZBAI 0.00
  • BCTX 65.43

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

About BCTX BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Share on Social Networks: